Finanzen von Ping An Biomedical Co Ltd (PASW)PASWPing An Biomedical Co Ltd

Evaluating the bottom line, Ping An Biomedical Co Ltd maintains a gross margin of 2.78%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -43.05%, while the net margin is -37.57%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively PASW converts its operational activities into shareholder value.

The financial performance shows a concerning trend with negative EPS projections, including -0.24 for Q2 2025 and -0.69 for Q4 2025. The gross margin is also low, with a projected 2.78% for Q4 2025, indicating challenges in maintaining profitability.